Pivotal Validation Study of Salivary Biomarkers for the Risk Stratification of Patients With Lesions Suspicious for Oral Squamous Cell Carcinoma
Observational
Observational Model: Case Control, Time Perspective: Prospective
Test specificity over 50% at 90% sensitivity
at study completion
No
Barry Wenig, MD
Principal Investigator
Michigan State University
United States: Institutional Review Board
PeriRx-1
NCT01587573
April 2012
May 2014
Name | Location |
---|---|
University of Michigan | Ann Arbor, Michigan 48109-0624 |
Department of Surgery, Michigan Sate University | East Lansing, Michigan 48912 |